Author/Authors :
Spiliopoulou, Pavlina Beatson West of Scotland Cancer Centre (BWoSCC) - Glasgow, UK , Fleming, Kathryn Beatson West of Scotland Cancer Centre (BWoSCC) - Glasgow, UK , McGuinness, James Beatson West of Scotland Cancer Centre (BWoSCC) - Glasgow, UK , Glen, Hilary Beatson West of Scotland Cancer Centre (BWoSCC) - Glasgow, UK , Kipgen, David Queen Elizabeth University Hospital - Glasgow, UK
Abstract :
We describe a case of lenvatinib (E7080) associated focal segmental glomerulosclerosis (FSGS) encountered during the treatment ofmetastatic medullary thyroid cancer. Proteinuria is a relatively common side effect of VEGF-targeted treatments and canoccasionally result in treatment discontinuation. Here, we describe a patient who developed secondary FSGS necessitatingdiscontinuation of treatment atfirst but who was subsequently rechallenged with anti-VEGF-targeted treatment withoutrecurrence of proteinuria. Lenvatinib was a novel experimental agent at the time the treatment took place; however, its recentlicensing for the treatment of thyroid malignancies in the UK makes reporting of these adverse effects all the more important now
Keywords :
Focal Segmental Glomerulosclerosis (FSGS) , Lenvatinib-Induced , Metastatic Medullary Thyroid Cancer
